litlas
Log inCreate account

James C. Yao

Active 2003–2025

Also published as
James C Yao
122
Papers
35,469
Citations
81
h-index
117
i10-index

Citations

Citations per year for James C. Yao1984: 2 citations1994: 2 citations1997: 1 citations2003: 3 citations2004: 4 citations2005: 33 citations2006: 74 citations2007: 75 citations2008: 114 citations2009: 125 citations2010: 205 citations2011: 251 citations2012: 279 citations2013: 279 citations2014: 304 citations2015: 250 citations2016: 228 citations2017: 314 citations2018: 326 citations2019: 1,152 citations2020: 1,235 citations2021: 1,065 citations2022: 772 citations2023: 609 citations2024: 1,044 citations2025: 461 citations2026: 4 citations1985–1993: no citations, so these years are not shown1995–1996: no citations, so these years are not shown1998–2002: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,174 citing papers, 24.1% of this breakdownChina: 821 citing papers, 9.1% of this breakdownItaly: 717 citing papers, 8% of this breakdownGermany: 629 citing papers, 7% of this breakdownUnited Kingdom: 500 citing papers, 5.5% of this breakdownFrance: 445 citing papers, 4.9% of this breakdownNetherlands: 367 citing papers, 4.1% of this breakdownJapan: 295 citing papers, 3.3% of this breakdownCanada: 281 citing papers, 3.1% of this breakdownSwitzerland: 260 citing papers, 2.9% of this breakdownSpain: 256 citing papers, 2.8% of this breakdownSweden: 215 citing papers, 2.4% of this breakdown
0%24.1%Other 22.8%

Institutions

Fields

  • Medicine81.4%
  • Biochemistry, Genetics and Molecular Biology15.4%
  • Immunology and Microbiology0.6%
  • Materials Science0.4%
  • Computer Science0.4%
  • Engineering0.4%
  • Other1.4%

Topics

  • Neuroendocrine Tumor Research Advances17.7%
  • Lung Cancer Research Studies11.6%
  • Neuroblastoma Research and Treatments6.6%
  • Pancreatic and Hepatic Oncology Research5%
  • Radiopharmaceutical Chemistry and Applications3.2%
  • Thyroid Cancer Diagnosis and Treatment2.1%
  • Other53.8%

Coauthors

All papers

Open in search
  1. Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

    Authors: Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, Andrew Hendifar, James C. Yao, Beth Chasen, Erik Mittra, Pamela L. Kunz, Matthew H. Kulke, Heather A. Jacene, David Bushnell, Thomas M. O’Dorisio, Richard P. Baum, Harshad Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy J. Hobday, Ebrahim S. Delpassand, Eric Van Cutsem, Al B. Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Font de Mora, Jordan Berlin, Enrique Grande, Nicholas S. Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L. Erion, Philippe Ruszniewski, Dik J. Kwekkeboom, Eric P. Krenning - New England Journal of Medicine 2017 cited by 3,178

  2. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

    Authors: Arvind Dasari, Chan Shen, Daniel M. Halperin, Bo Zhao, Shouhao Zhou, Ying Xu, Ya‐Chen Tina Shih, James C. Yao - JAMA Oncology 2017 cited by 3,468

  3. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

    Authors: Jonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, Philippe B Ruszniewski, Lisa Bodei, Andrew Hendifar, Erik Mittra, Edward M Wolin, James C Yao, Marianne E Pavel, Enrique Grande, Eric Van Cutsem, Ettore Seregni, Hugo Duarte, Germo Gericke, Amy Bartalotta, Maurizio F Mariani, Arnaud Demange, Sakir Mutevelic, Eric P Krenning - The Lancet Oncology 2021 cited by 541

  4. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    Authors: Arvind Dasari, Sara Lonardi, Rocio García‐Carbonero, Elena Élez, Takayuki Yoshino, Alberto Sobrero, James C. Yao, Pilar García‐Alfonso, Judit Kocsis, Antonio Cubillo Gracián, Andrea Sartore‐Bianchi, Taroh Satoh, Violaine Randrian, Jiří Tomášek, Geoff Chong, Andrew Scott Paulson, Toshiki Masuishi, Jeremy Jones, Tibor Csőszi, Chiara Cremolini, François Ghiringhelli, Ardaman Shergill, Howard S. Höchster, John C. Krauss, Ali Bassam, Michel Ducreux, Anneli Elme, Laurence Faugeras, Stefan Kasper, Eric Van Cutsem, Dirk Arnold, Shivani Nanda, Zhao Yang, William R. Schelman, Marek Kania, Josep Tabernero, Cathy Eng - The Lancet 2023 cited by 323

  5. One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

    Authors: James C. Yao, Manal M. Hassan, Alexandria T. Phan, Cecile G. Dagohoy, Colleen Leary, Jeannette E. Mares, Eddie K. Abdalla, Jason B. Fleming, Jean‐Nicolas Vauthey, Asif Rashid, Douglas B. Evans - Journal of Clinical Oncology 2008 cited by 4,526

  6. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

    Authors: Ahmed O. Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, Lianchun Xiao, Jean‐Nicolas Vauthey, Sunyoung S. Lee, Betül Gök Yavuz, Yehia I. Mohamed, Aliya Qayyum, Sonali Jindal, Fei Duan, Sreyashi Basu, Shalini S. Yadav, Courtney Nicholas, Jing Sun, Kanwal Raghav, Asif Rashid, Kristen Carter, Yun Shin Chun, Ching‐Wei D. Tzeng, Divya Sakamuri, Li Xu, Ryan Sun, Vittorio Cristini, Laura Beretta, James C. Yao, Robert A. Wolff, James P. Allison, Padmanee Sharma - ˜The œLancet. Gastroenterology & hepatology 2022 cited by 256

  7. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    Authors: James C. Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Edward M. Wolin, Jiří Tomášek, Markus Raderer, Harald Lahner, Maurizio Voi, Lida Pacaud, Nicolas Rouyrre, Carolin Sachs, Juan W. Valle, Gianfranco Delle Fave, Eric Van Cutsem, Margot Tesselaar, Yasuhiro Shimada, Do‐Youn Oh, Jonathan Strosberg, Matthew H. Kulke, Marianne Pavel - The Lancet 2015 cited by 1,264

  8. Everolimus for Advanced Pancreatic Neuroendocrine Tumors

    Authors: James C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg - New England Journal of Medicine 2011 cited by 2,848

  9. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

    Authors: Pamela L. Kunz, Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre, Carlos J. Suarez, Brock A. Martin, James C. Yao, Matthew H. Kulke, Andrew Hendifar, James C. Shanks, Manisha H. Shah, Mark M. Zalupski, Edmond L. Schmulbach, Diane Reidy‐Lagunes, Jonathan Strosberg, Peter J. O’Dwyer, Al B. Benson - Journal of Clinical Oncology 2022 cited by 294

  10. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

    Authors: Valentina Ambrosini, Jolanta Kunikowska, Eric Baudin, Lisa Bodei, Catherine Bouvier, Jaume Capdevila, Marta Cremonesi, Wouter W. de Herder, Clarisse Dromain, Massimo Falconi, Melpomeni Fani, Stefano Fanti, Rodney J. Hicks, Levent Kabasakal, Gregory Kaltsas, Valerie Lewington, Silvia Minozzi, Michela Cinquini, Kjell Öberg, Wim J.G. Oyen, Dermot O’Toole, Marianne Pavel, Philippe Ruszniewski, Aldo Scarpa, Jonathan Strosberg, Anders Sundin, David Taïeb, Irene Virgolini, Damian Wild, Ken Herrmann, James C. Yao - European Journal of Cancer 2021 cited by 242

  11. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

    Authors: Marianne Pavel, John D. Hainsworth, Éric Baudin, Marc Peeters, Dieter Hörsch, Robert Winkler, Judith Klimovsky, David Lebwohl, Valentine Jehl, Edward M. Wolin, Kjell Öberg, Eric Van Cutsem, James C. Yao - The Lancet 2011 cited by 1,052

  12. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

    Authors: Jonathan Strosberg, Þorvarður R. Hálfdánarson, Andrew M. Bellizzi, Jennifer A. Chan, Joseph S. Dillon, Anthony P. Heaney, Pamela L. Kunz, Thomas M. O’Dorisio, Riad Salem, Eva Segelov, James R. Howe, Rodney F. Pommier, Kari Brendtro, Mohammad Bashir, Simron Singh, Michael C. Soulen, Laura Tang, Jerome Zacks, James C. Yao, Emily K. Bergsland - Pancreas 2017 cited by 366

  13. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms

    Authors: James C. Yao, Emily K. Bergsland, Rahul Aggarwal, Ana M. Aparicio, Himisha Beltran, Judy S. Crabtree, Christine L. Hann, Toni Ibrahim, Lauren A. Byers, Hironobu Sasano, John Umejiego, Marianne Pavel - The Oncologist 2022 cited by 85

  14. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study

    Authors: Daniel M. Halperin, Chan Shen, Arvind Dasari, Ying Xu, Yiyi Chu, Shouhao Zhou, Ya‐Chen Tina Shih, James C. Yao - The Lancet Oncology 2017 cited by 385

  15. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ

    Authors: Yi Liu, Yasunori Deguchi, Daoyan Wei, Fuyao Liu, Micheline J. Moussalli, Eriko Deguchi, Donghui Li, Huamin Wang, Lovie Ann Valentin, Jennifer K. Colby, Jing Wang, Xiaofeng Zheng, Haoqiang Ying, Mihai Gagea, Baoan Ji, Jiaqi Shi, James C. Yao, Xiangsheng Zuo, Imad Shureiqi - Nature Communications 2022 cited by 68

  16. The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors

    Authors: J. Philip Boudreaux, David S. Klimstra, Manal M. Hassan, Eugene A. Woltering, Robert T. Jensen, Stanley J. Goldsmith, Charles Nutting, David Bushnell, Martyn Caplin, James C. Yao - Pancreas 2010 cited by 532

  17. Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms

    Authors: James C. Yao, Jonathan Strosberg, Nicola Fazio, Marianne Pavel, Emily K. Bergsland, Philippe Ruszniewski, Daniel M. Halperin, Daneng Li, Salvatore Tafuto, Nitya Raj, Davide Campana, Susumu Hijioka, Markus Raderer, Rosine Guimbaud, Pablo Gajate, Sara Pusceddu, Albert Reising, Evgeny Degtyarev, Mark Shilkrut, Simantini Eddy, Simron Singh - Endocrine Related Cancer 2021 cited by 106

  18. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018

    Authors: Manisha H. Shah, Whitney Goldner, Þorvarður R. Hálfdánarson, Emily K. Bergsland, Jordan Berlin, Daniel M. Halperin, Jennifer A. Chan, Matthew H. Kulke, Al B. Benson, Lawrence S. Blaszkowsky, Jennifer R. Eads, Paul F. Engstrom, Paul T. Fanta, Thomas J. Giordano, Jin He, Martin J. Heslin, Gregory P. Kalemkerian, Fouad Kandeel, Sajid Khan, Wajih Zaheer Kidwai, Pamela L. Kunz, Boris W. Kuvshinoff, Christopher H. Lieu, Venu G. Pillarisetty, Leonard B. Saltz, Julie Ann Sosa, Jonathan Strosberg, Craig A. Sussman, Nikolaos A. Trikalinos, N. Uboha, Jonathan Whisenant, Terence Z. Wong, James C. Yao, Jennifer L. Burns, Ndiya Ogba, Griselda Zuccarino-Catania - Journal of the National Comprehensive Cancer Network 2018 cited by 391

  19. Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?

    Authors: Michael J. Overman, Janhavi Modak, Scott Kopetz, Ravi Murthy, James C. Yao, Marshall E. Hicks, James L. Abbruzzese, Alda L. Tam - Journal of Clinical Oncology 2012 cited by 310

  20. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study

    Authors: James C. Yao, Marianne Pavel, Catherine Lombard‐Bohas, Eric Van Cutsem, Maurizio Voi, Ulrike Brandt, Wei He, David Chen, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Timothy J. Hobday, Rodney F. Pommier, Kjell Öberg - Journal of Clinical Oncology 2016 cited by 269

  21. Neuroendocrine Tumors, Version 1.2015

    Authors: Matthew H. Kulke, Manisha H. Shah, Al B. Benson, Emily K. Bergsland, Jordan Berlin, Lawrence S. Blaszkowsky, Lyska L. Emerson, Paul F. Engstrom, Paul T. Fanta, Thomas J. Giordano, Whitney Goldner, Þorvarður R. Hálfdánarson, Martin J. Heslin, Fouad Kandeel, Pamela L. Kunz, Boris W. Kuvshinoff, Christopher H. Lieu, Jeffrey F. Moley, Gitonga Munene, Venu G. Pillarisetty, Leonard B. Saltz, Julie Ann Sosa, Jonathan Strosberg, Jean‐Nicolas Vauthey, Christopher L. Wolfgang, James C. Yao, Jennifer Burns, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2015 cited by 356

  22. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases

    Authors: Arvind Dasari, Kathan Mehta, Lauren A. Byers, Halfdan Sørbye, James C. Yao - Cancer 2017 cited by 272

  23. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

    Authors: on behalf of the NETTER-1 study group, Jonathan Strosberg, Pamela L. Kunz, Andrew Hendifar, James C. Yao, David Bushnell, Matthew H. Kulke, Richard P. Baum, Martyn Caplin, Philippe Ruszniewski, Ebrahim S. Delpassand, Timothy J. Hobday, Chris Verslype, Al B. Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaume Mora, Jordan Berlin, Enrique Grande, Nicholas S. Reed, Ettore Seregni, Giovanni Paganelli, Stefano Severi, Michael Morse, David C. Metz, C. Ansquer, F. Courbon, Adil Al‐Nahhas, Eric Baudin, Francesco Giammarile, David Taïeb, Erik Mittra, Edward M. Wolin, Thomas M. O’Dorisio, Rachida Lebtahi, Christophe M. Deroose, Chiara Maria Grana, Lisa Bodei, Kjell Öberg, Berna Polack, Beilei He, Maurizio Mariani, Germo Gericke, Paola Santoro, Jack L. Erion, Laura Ravasi, Eric P. Krenning - European Journal of Nuclear Medicine and Molecular Imaging 2020 cited by 127

  24. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

    Authors: Ahmed O. Kaseb, Nora Sánchez, Shiraj Sen, Robin Kate Kelley, Benjamin Tan, Andrea Grace Bocobo, Kian‐Huat Lim, Reham Abdel‐Wahab, Marc Uemura, Roberto Carmagnani Pestana, Wei Qiao, Lianchun Xiao, Jeffrey S. Morris, Hesham M. Amin, Manal M. Hassan, Asif Rashid, Kimberly C. Banks, Richard B. Lanman, AmirAli Talasaz, Kenna R. Mills-Shaw, Bhawana George, Abedul Haque, Kanwal Raghav, Robert A. Wolff, James C. Yao, Funda Meric‐Bernstam, Sadakatsu Ikeda, Razelle Kurzrock - Clinical Cancer Research 2019 cited by 76